Analysts think SONN stock price could increase by 3720%
Aug 02, 2024, 6:25 AM
-8.74%
What does SONN do
Sonnet BioTherapeutics Holdings, Inc., headquartered in Princeton, New Jersey, is a clinical-stage biotech company focused on oncology, utilizing its Fully Human Albumin Binding technology to enhance drug delivery in cancer treatment. Key products include SON-1010 for solid tumors and SON-080 for neuropathy conditions, with additional assets in development.
5 analysts think SONN stock price will increase by 3720.22%. The current median analyst target is $30.60 compared to a current stock price of $0.80. The lowest analysts target is $7.07 and the highest analyst target is $46.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
